Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

Fig. 3

PFS according to MDR1 G2677 T polymorphism. Patients with GT in the site of the MDR1 G2677 T polymorphism lived longer without disease progression [median PFS: 8.6 months, mean PFS ± SE: 16.2 months ±5 (95% CI: 6.3–26)] than patients with GG at the same site [median PFS: 5.1 months, mean PFS ± SE: 7.2 ± 1.5 (95% CI: 4.2–10.20)], who in turn had longer progression-free survival than patients with TT at the same site [median PFS: 2.9 months, mean PFS ± SE: 4 months ±1.3 (95% CI: 1.4–6.6)] (p = 0.027). PFS, Progression Free Survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us